Sanofi-Aventis redoubles efforts in Chinese market

15:45, May 17, 2011      

Email | Print | Subscribe | Comments | Forum 



China is now the world's second-largest consumer healthcare market after the United States, and was estimated to be worth around $9.89 billion in 2008. Chen Hao / For China Daily

China may become the second-largest market for the French pharmaceutical company Sanofi-Aventis SA within five years, according to the company's Chief Executive Officer Christopher A. Viehbacher.

He added that goal has prompted the drugmaker to redouble its efforts in its consumer health business and in vaccines for flu and other diseases during the coming years.

This year, Sanofi-Aventis expects revenue of about 100 million euros ($141 million) - out of a global total of 3 billion euros - from its consumer health business in China, said Viehbacher.

"The Chinese government has made health a major priority. We hope we can be more involved in China's health reforms and meet the needs of the people," he said.

Favorable market trends, such as increasing consumer awareness of health issues, and the government's focus on health are also providing increased opportunities.

Last year, Sanofi-Aventis acquired the Chinese drug company BMP Sunstone Corp for $521 million. The move not only gave Sanofi control of BMP's treatments for coughs, colds, and women's health products but also access to a well-established distribution network in the sector.

Last year, the company also set up a joint venture in vitamin and mineral supplements with Hangzhou Minsheng Pharmaceutical Group Co Ltd. "We have a 15-year collaboration with Minsheng and have established a good relationship. We believe that Minsheng's 21 Super-Vita, the well-known line of vitamin products, has great brand value," said the CEO. Viehbacher added that the joint venture will help Sanofi-Aventis to consolidate its position in China's consumer health business.

China is now the world's second-largest consumer healthcare market after the United States, and was estimated to be worth around $9.89 billion in 2008. Sanofi-Aventis says it expects to generate "double-digit" sales growth over the next five years.



The Paris-based company has been expanding in emerging markets and consumer health products to counter a loss of revenue caused by the expiry of the patents on some of its best-selling drugs.

Despite being ranked fifth in the global "over the counter" (OTC) market, Sanofi-Aventis is still a newcomer in China's OTC market, meaning mergers and acquisitions will be an important strategy, according to Thomas Kelly, senior vice-president of Sanofi-Aventis Asia.

"We are just tapping into the OTC market, so collaborating with established brands and excellent products that have wide distribution channels is a very efficient way for us to compete. We will continue to look for other good opportunities for collaboration or acquisitions," said Kelly.

"However, we are in no hurry to do that, because we have our own line of consumer health products, which is expected to be launched in China this year," he added.

Last week, Sanofi-Aventis launched its five-in-one combination children's vaccine Pentaxim in China.

The company says the treatment is effective against several of the most prominent childhood illnesses such as diphtheria, tetanus, polio and Haemophilus influenzae type B.

The vaccine will also help lower the number of shots required for immunization from 12 to four.

Meanwhile, the company is building a factory in Shenzhen, Guangdong province, which will produce flu vaccine for 2013. The drugmaker also expects to launch a dengue vaccine in the country in 2014 or 2015.

Viehbacher said Sanofi also sees opportunities for treatment aimed at other illnesses, such as liver cancer, and will increase investment in manufacturing, research and development, and will cooperate with universities.

The company has also announced that it will support a five-year plan for diabetes management established by China's health ministry. The program, led by the Chinese Center for Disease Control, will train 500 diabetes specialists, and provide 10,000 community and rural-based doctors to deliver diabetes care and patient education by 2015.

Source: China Daily

 
 
     
 
BRICS Leaders Meeting 2011
 
Japan in aftershocks
 
     
 
 
 
  Weekly review  
 
May 12   No winners in U.S. hi-tech export controls
 
May 12   China should view livelihood issues from strategic perspective
May 11   Syria will not be another Libya
May 06   Beijing-Shanghai high-speed railway to launch 10-day trial run
May 14   The week in pictures
May 11   2000-year-old wine unearthed in Henan province
May 11   Scientist: China plans to build lunar research base
May 09   Apple employee, customer reach settlement after Beijing iPad brawl
May 12   Wenchuan Reconstruction: 'Chinese miracle' impresses world
May 12   No winners in U.S. hi-tech export controls
 
     
 
 

(Editor:石希)

  • Do you have anything to say?

双语词典
dictionary

  
Special Coverage
  • 3rd Anniversary Of Wenchuan Earthquake
  • Third China-U.S. Strategic and Economic Dialogue
Major headlines
Editor's Pick
  • Millennium City Park showcases prosperity in Kaifeng 1,000 years ago
  • WHO opens 64th World Health Assembly in Geneva
  • Gharrafa beat Lekhwiya at Emir Cup
  • Sacred mountain and lake in SW China's Tibet
  • HKCU confers honorary fellowship
  • 7th China Int'l Culture Industry Fair concludes in Shenzhen
Hot Forum Dicussion